In the latest development, Ghent-based biotech startup myNEO announced that it has identified promising COVID-19 peptides that will undergo further preclinical testing in collaboration with a European biotech company with a cancer vaccine technology. The goal is to test the vaccine in early 2021 on humans.
Long term protection
Leveraging the existing cancer treatment technology, the COVID-19 vaccine aims to provide long-term protection to more than 80% of the global population. The startup, which is supported by Start it @KBC is developing a carefully chosen cocktail of peptides (pieces of protein) that are essential for the virus, to initiate a highly targeted immune response.